Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 11
Submit an article Journal homepage
420
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation

Jean El CheikhDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Correspondence[email protected]
,
Radwan MassoudDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;
,
Basel HaffarDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;
,
Elie FaresDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;
,
Rami MahfouzDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;
,
Tamima JisrDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;
,
Mohamed A. Kharfan-DabajaDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL, USA
,
Anas MougharbelDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;
,
Ali YoussefDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;
,
Ali BazarbachiDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;
&
Ahmad IbrahimDivision of Hematology and Oncology, Makassed University hospital, Beirut, Lebanon;
show all
Pages 2745-2747 | Received 04 Jan 2017, Accepted 06 Mar 2017, Published online: 28 Mar 2017

References

  • Andre M, Henry-Amar M, Pico JL, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. JCO. 1999;17:222–229.
  • Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117:4208–4217.
  • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–2189.
  • Salihoglu A, Elverdi T, Karadogan I, et al. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2015;94:415–420.
  • Kahraman D, Theurich S, Rothe A, et al. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Leuk Lymphoma. 2014;55:811–816.
  • Mian M, Farsad M, Pescosta N, et al. Bendamustine salvage for the treatment of relapsed Hodgkin’s lymphoma after allogeneic bone marrow transplantation. Ann Hematol. 2013;92:121–123.
  • Magyari F, Simon Z, Barna S, et al. Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation. Hematol Oncol. 2012;30:98–100.
  • Anastasia A, Carlo-Stella C, Corradini P, et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol. 2014;166:140–142.
  • Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146:158–163.
  • Corazzelli G, Angrilli F, D’Arco A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013;160:207–215.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
  • Ghesquieres H, Stamatoullas A, Casasnovas O, et al. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leuk Lymphoma. 2013;54:2399–2404.
  • Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31:456–460.
  • Howell M, Gibb A, Radford J, et al. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin. Br J Haematol. 2016. DOI:10.1111/bjh.14257
  • Zinzani PL, Vitolo U, Viviani S, et al. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma: experience with 27 patients. Clin Lymphoma Myeloma Leuk. 2015;15:404–408.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.